SCHEMBL4292679

SCHEMBL4292679

Fc1ccc(-c2ncn(CCCN3CCCC3)c2-c2ccc3[nH]ncc3c2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.84
MAP4K4 O95819 1/20 0.75
ERBB2 P04626 1/20 0.75
MAPK9 P45984 1/20 0.75
CSNK1D P48730 1/20 0.75
PRKD2 Q9BZL6 1/20 0.75
SLK Q9H2G2 1/20 0.75
MAPK13 O15264 14/20 0.64
MAPK12 P53778 14/20 0.64
MAPK11 Q15759 14/20 0.64
MAPK14 Q16539 14/20 0.64
TGFBR1 P36897 1/20 0.48
AURKA O14965 1/20 0.48
DAPK3 O43293 1/20 0.48
ROCK2 O75116 1/20 0.48
CHEK2 O96017 1/20 0.48
CDK1 P06493 1/20 0.48
PRKACA P17612 1/20 0.48
CDK2 P24941 1/20 0.48
MARK3 P27448 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667850 0.93 EGFR (0.82) EGFRMAP4K4ERBB2MAPK9CSNK1D
SCHEMBL3668156 0.91 EGFR (1.00) EGFRMAP4K4ERBB2MAPK9CSNK1D
SCHEMBL3669992 0.86 EGFR (1.00) EGFRMAP4K4ERBB2MAPK9CSNK1D
SCHEMBL3668088 0.83 EGFR (0.78) EGFRMAP4K4ERBB2MAPK9CSNK1D
SCHEMBL3667999 0.83 EGFR (0.88) EGFRMAP4K4ERBB2MAPK9CSNK1D
SCHEMBL3670894 0.81 EGFR (1.00) EGFRMAP4K4ERBB2MAPK9CSNK1D
SCHEMBL4289377 0.80 EGFR (0.65) EGFRMAP4K4ERBB2MAPK9CSNK1D
SCHEMBL4906627 0.79 MAPK13 (1.00) MAP4K4MAPK9CSNK1DMAPK13MAPK12
SCHEMBL8860437 0.79 MAPK13 (1.00) MAP4K4MAPK9CSNK1DMAPK13MAPK12
SCHEMBL8860442 0.78 MAPK13 (1.00) MAP4K4MAPK9CSNK1DMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 EGFR 876/4885MAP4K4 51/4885ERBB2 345/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 EGFR 876/4885MAP4K4 51/4885ERBB2 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.